Jump to main content
Jump to site search


Organotin compound DBDCT induces CYP3A suppression through NF-κB-mediated repression of PXR activity

Author affiliations

Abstract

Organotin anticancer agent di-n-butyl-di-(4-chlorobenzohydroxamato)tin(IV) (DBDCT) exerted an inhibitory effect on its major metabolic enzyme cytochrome CYP3A. But whether hepatic drug-metabolizing enzymes and their regulatory nuclear receptors including pregnane PXR and constitutive androstane CAR binding with retinoid receptor RXR as a heterodimer are involved in the DBDCT-mediated regulation of CYP3A remains unclear. This study was undertaken to determine the mechanisms responsible for the effects of DBDCT on CYP3A suppression, focusing on the PXR-mediated and NF-κB pathways. The results indicated DBDCT suppressed CYP3A expression by inhibiting CAR expression. But what's interesting is, both protein and mRNA of PXR increased with increasing DBDCT. A further exploration, dual luciferase reporter gene analysis, clarified that DBDCT induced CYP3A expression elevation via the PXR-mediated pathway and this induction was countered by activation of NF-κB, which played a pivotal role in suppression of CYP3A through disrupting the association of the PXR–RXRα complex with DNA sequences by EMSA. PXR-mediated CYP3A expression was similarly demonstrated by RNAi. As expected, expression of CYP3A and its mRNA levels were reduced by DBDCT only in NF-κB(+/+) but not in NF-κB(−/−) cells. The inductive effect of DBDCT on CYP3A4 mRNA was enhanced in PXR shRNA-transfected cells but weakened in the ip65 group, which showed both PXR up-regulated CYP3A expression and NF-κB p65 activation directly contributed to CYP3A inhibition. In conclusion, activated NF-κB by DBDCT interacts directly with the DNA-binding domain of PXR, and disrupts the binding between the PXR–RXR dimer, thereby affecting the regulatory process for CYP3A transcription and, therefore, leading to a decrease of the expression of the PXR-regulated CYP3A.

Graphical abstract: Organotin compound DBDCT induces CYP3A suppression through NF-κB-mediated repression of PXR activity

Back to tab navigation

Publication details

The article was received on 13 Dec 2018, accepted on 20 Feb 2019 and first published on 08 Mar 2019


Article type: Paper
DOI: 10.1039/C8MT00361K
Citation: Metallomics, 2019, Advance Article

  •   Request permissions

    Organotin compound DBDCT induces CYP3A suppression through NF-κB-mediated repression of PXR activity

    Y. Li, N. Lin, X. Ji, J. Mai and Q. Li, Metallomics, 2019, Advance Article , DOI: 10.1039/C8MT00361K

Search articles by author

Spotlight

Advertisements